



Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

July 29, 2017

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Press Release

Please find enclosed press release for the financial results for the quarter ended June 30, 2017.

Please take the above on record.

Thanking you,

Yours truly,
For Pfizer Limited

Prajeet Nair
Company Secretary

Encl: A/a



Press Release
For immediate dissemination

Pfizer Limited Revenue from operations at ₹432.6 crore for the quarter ended June 30, 2017

Pfizer Limited announced its results for the quarter ended June 30, 2017.

Revenues

Revenue from operations for the quarter ended June 30, 2017 were ₹432.6 crore as compared to ₹520.9 crore in the same period last year

The revenue for the quarter, when compared with the same period last year, has been impacted by discontinuation of Corex cough syrup and transition / divesture of certain brands last year.

Adjusting for the impact of the above, the revenue of 'continuing business' declined by 3% for the quarter ended June 30, 2017.

The revenue decline in 'continuing business' is mainly due to the reduction of inventory by trade due to GST transition. This has impacted the industry in general.

Profits before other income, exceptional items and tax

Profit from operations (before other income, exceptional items and tax) for the quarter ended June 30, 2017 is ₹61.2 crore as compared to ₹85.7 crore in the same period last year. The decline in profit is primarily due to factors stated above.

EBITDA

EBITDA for quarter ended June 30, 2017 is at 17.7%.

Profit after tax

Net Profit after tax (including other comprehensive income) for the quarter is ₹56.9 crore as against ₹80.4 crore in the same period last year. The comparable quarter ending June 30, 2016 had an exceptional income of ₹7.9 crore on account of income from sale of property, net of related expenses.

For more information,

Investors:

Prajeet Nair

Pfizer Limited

Ph.: +91-22-66932352

Email: prajeet.nair@pfizer.com

Media:

Saritha Rajeev Hajare

Pfizer Limited

+ 91 9619990917

saritha.hajare@pfizer.com

About Pfizer Limited:

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading Biopharmaceutical Company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 60 years in India, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizerindia.com

Disclaimer

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries where such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advise may be obtained and necessary due diligence, investigation etc. may be done at your end.